Apixaban - Metabolism, Pharmacologic Properties and Drug Interactions
Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.org..
BACKGROUND: Apixaban is an oral, potent, highly selective, reversible and direct inhibitor of activated coagulation factor X, that is the end point of the intrinsic and extrinsic coagulation pathway. Additionally, apixaban has the capacity to indirectly inhibit thrombin-induced platelet aggregation. This new oral anticoagulant represents an immediate-release form of peroral drug with quick dissolution, linear pharmacokinetics, good bioavailability and rapid onset and offset of action. No clinically relevant age- or sex-dependent difference in the apixaban pharmacokinetics and pharmacodynamics which would lead to the modification of the dose exists, apixaban may even be administered with or without food. Its elimination is mediated by metabolism, renal elimination of unmodified drug and excretion in the gastrointestinal tract.
OBJECTIVE: The authors aim to provide a review of currently available literature about apixaban.
METHOD: The authors summed-up the data from the scientific journals related to thrombosis and hemostasis and searched the available databases.
RESULTS AND CONCLUSION: Apixaban has many advantages including predictable pharmacokinetics and pharmacodynamics, low number of drug and food interactions, and relatively wide therapeutic window.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2017 |
|---|---|
| Erschienen: |
2017 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:18 |
|---|---|
| Enthalten in: |
Current drug metabolism - 18(2017), 7 vom: 30., Seite 609-621 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kubisz, Peter [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
3Z9Y7UWC1J |
|---|
| Anmerkungen: |
Date Completed 10.09.2018 Date Revised 10.09.2018 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.2174/1389200218666170424151551 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM271265167 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM271265167 | ||
| 003 | DE-627 | ||
| 005 | 20231224232335.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2017 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2174/1389200218666170424151551 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0904.xml |
| 035 | |a (DE-627)NLM271265167 | ||
| 035 | |a (NLM)28440204 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kubisz, Peter |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Apixaban - Metabolism, Pharmacologic Properties and Drug Interactions |
| 264 | 1 | |c 2017 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 10.09.2018 | ||
| 500 | |a Date Revised 10.09.2018 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.org. | ||
| 520 | |a BACKGROUND: Apixaban is an oral, potent, highly selective, reversible and direct inhibitor of activated coagulation factor X, that is the end point of the intrinsic and extrinsic coagulation pathway. Additionally, apixaban has the capacity to indirectly inhibit thrombin-induced platelet aggregation. This new oral anticoagulant represents an immediate-release form of peroral drug with quick dissolution, linear pharmacokinetics, good bioavailability and rapid onset and offset of action. No clinically relevant age- or sex-dependent difference in the apixaban pharmacokinetics and pharmacodynamics which would lead to the modification of the dose exists, apixaban may even be administered with or without food. Its elimination is mediated by metabolism, renal elimination of unmodified drug and excretion in the gastrointestinal tract | ||
| 520 | |a OBJECTIVE: The authors aim to provide a review of currently available literature about apixaban | ||
| 520 | |a METHOD: The authors summed-up the data from the scientific journals related to thrombosis and hemostasis and searched the available databases | ||
| 520 | |a RESULTS AND CONCLUSION: Apixaban has many advantages including predictable pharmacokinetics and pharmacodynamics, low number of drug and food interactions, and relatively wide therapeutic window | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Apixaban | |
| 650 | 4 | |a anti-Xa activity | |
| 650 | 4 | |a bleeding | |
| 650 | 4 | |a drug interactions | |
| 650 | 4 | |a elimination | |
| 650 | 4 | |a metabolism | |
| 650 | 4 | |a new oral anticoagulants | |
| 650 | 4 | |a pharmacology | |
| 650 | 7 | |a Factor Xa Inhibitors |2 NLM | |
| 650 | 7 | |a Pyrazoles |2 NLM | |
| 650 | 7 | |a Pyridones |2 NLM | |
| 650 | 7 | |a apixaban |2 NLM | |
| 650 | 7 | |a 3Z9Y7UWC1J |2 NLM | |
| 700 | 1 | |a Stanciakova, Lucia |e verfasserin |4 aut | |
| 700 | 1 | |a Dobrotova, Miroslava |e verfasserin |4 aut | |
| 700 | 1 | |a Samos, Matej |e verfasserin |4 aut | |
| 700 | 1 | |a Mokan, Marian |e verfasserin |4 aut | |
| 700 | 1 | |a Stasko, Jan |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Current drug metabolism |d 2000 |g 18(2017), 7 vom: 30., Seite 609-621 |w (DE-627)NLM113669038 |x 1875-5453 |7 nnns |
| 773 | 1 | 8 | |g volume:18 |g year:2017 |g number:7 |g day:30 |g pages:609-621 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2174/1389200218666170424151551 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 18 |j 2017 |e 7 |b 30 |h 609-621 | ||